Every material Form 8-K AVITA Medical, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AVITA Medical reported third-quarter 2026 revenue of $26.1 million, up 53% from $17.1 million a year earlier, and raised its full-year 2026 revenue guidance to $92 million to $94 million. Net loss narrowed to $6.2 million ($0.20 per share) from $13.2 million ($0.46 per share), and the company drew the remaining $10.0 million under its Perceptive Advisors credit facility, which management said led it to conclude that substantial doubt about its ability to continue as a going concern had been alleviated.
Q3 2026 total revenue $26.1 million, up 53% from $17.1 million in Q3 2025
Full-year 2026 revenue guidance raised to $92 million to $94 million, from $86 million to $89 million
Net loss $6.2 million, or $0.20 per share, versus $13.2 million, or $0.46 per share, a year earlier
Cash and marketable securities of approximately $10.5 million at September 30, 2026; total facility borrowings reached $60 million after the $10.0 million draw
AVITA Medical disclosed that Perceptive Credit Holdings V exercised a warrant on October 26, 2026 through a cashless exercise, with the company withholding 112,284 shares to cover the exercise price and issuing 387,716 shares on October 28, 2026. The warrant was tied to a January 13, 2026 credit agreement and covered up to 500,000 shares, so the issuance adds new common shares outstanding for existing holders.
Perceptive exercised the warrant on October 26, 2026 via a cashless exercise.
The company withheld 112,284 shares to cover the exercise price.
The company issued 387,716 shares to Perceptive on October 28, 2026, out of a warrant for up to 500,000 shares.
The filing was lodged on the Australian Securities Exchange on November 2, 2026.
AVITA Medical signed a Global Amendment with Stedical Scientific dated August 5, 2026, changing their PermeaDerm distribution and manufacturing agreements. The company's revenue share rises to 67% for sheet-form products and 80% for glove-form products, and it gains a right of first offer on expanding its territory to parts of Europe, the UK, and Australia for a $500,000 fee.
Company pays a $500,000 fee for a right of first offer and refusal on expanding exclusive distribution to all or part of the EU, UK, and/or Australia.
Company's revenue share from PermeaDerm sales rises to 67% for sheet form and 80% for glove form, with revenue-sharing increases tied to gross margin thresholds of 50% and 35%.
For 2026 the company must reach $1.0 million in total PermeaDerm revenue sharing payments, with 20% annual growth minimums through 2030; prior minimum payment requirements were waived.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AVITA Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →